



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting (Review)

Chan CCH, Fage BA, Burton JK, Smailagic N, Gill SS, Herrmann N, Nikolaou V, Quinn TJ, Noel-Storr AH, Seitz DP

Chan CCH, Fage BA, Burton JK, Smailagic N, Gill SS, Herrmann N, Nikolaou V, Quinn TJ, Noel-Storr AH, Seitz DP.  
Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting.  
*Cochrane Database of Systematic Reviews* 2019, Issue 9. Art. No.: CD011414.  
DOI: 10.1002/14651858.CD011414.pub2.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	6
OBJECTIVES . . . . .	7
METHODS . . . . .	8
RESULTS . . . . .	10
Figure 1. . . . .	11
Figure 2. . . . .	12
Figure 3. . . . .	13
DISCUSSION . . . . .	14
AUTHORS' CONCLUSIONS . . . . .	14
ACKNOWLEDGEMENTS . . . . .	15
REFERENCES . . . . .	15
CHARACTERISTICS OF STUDIES . . . . .	19
DATA . . . . .	27
Test 1. Mini-Cog in secondary care. . . . .	27
ADDITIONAL TABLES . . . . .	27
APPENDICES . . . . .	29
CONTRIBUTIONS OF AUTHORS . . . . .	36
DECLARATIONS OF INTEREST . . . . .	37
SOURCES OF SUPPORT . . . . .	37
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	37

[Diagnostic Test Accuracy Review]

# Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting

Calvin CH Chan<sup>1</sup>, Bruce A Fage<sup>2</sup>, Jennifer K Burton<sup>3</sup>, Nadja Smailagic<sup>4</sup>, Sudeep S Gill<sup>5</sup>, Nathan Herrmann<sup>6</sup>, Vasilis Nikolaou<sup>7</sup>, Terry J Quinn<sup>8</sup>, Anna H Noel-Storr<sup>9</sup>, Dallas P Seitz<sup>10</sup>

<sup>1</sup>School of Medicine, Queen's University, Kingston, Canada. <sup>2</sup>Department of Psychiatry, University of Toronto, Toronto, Canada. <sup>3</sup>Academic Geriatric Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. <sup>4</sup>Institute of Public Health, University of Cambridge, Cambridge, UK. <sup>5</sup>Department of Medicine, Queen's University, Kingston, Canada. <sup>6</sup>Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Canada. <sup>7</sup>Research In Real Life, Cambridge, UK. <sup>8</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK. <sup>9</sup>Radcliffe Department of Medicine, University of Oxford, Oxford, UK. <sup>10</sup>Department of Psychiatry, Queen's University, Kingston, Canada

Contact address: Dallas P Seitz, Department of Psychiatry, Queen's University, 752 King Street West, Kingston, ON, K7L 4X3, Canada. [seitzd@providencecare.ca](mailto:seitzd@providencecare.ca).

**Editorial group:** Cochrane Dementia and Cognitive Improvement Group.

**Publication status and date:** New, published in Issue 9, 2019.

**Citation:** Chan CCH, Fage BA, Burton JK, Smailagic N, Gill SS, Herrmann N, Nikolaou V, Quinn TJ, Noel-Storr AH, Seitz DP. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. *Cochrane Database of Systematic Reviews* 2019, Issue 9. Art. No.: CD011414. DOI: 10.1002/14651858.CD011414.pub2.

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.

### Objectives

The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources of heterogeneity will include the baseline prevalence of dementia in study samples, thresholds used to determine positive test results, the type of dementia (Alzheimer's disease dementia or all causes of dementia), and aspects of study design related to study quality.

### Search methods

We searched the following sources in September 2012, with an update to 12 March 2019: Cochrane Dementia Group Register of Diagnostic Test Accuracy Studies, MEDLINE (OvidSP), Embase (OvidSP), BIOSIS Previews (Web of Knowledge), Science Citation Index (ISI Web of Knowledge), PsycINFO (OvidSP), and LILACS (BIREME). We made no exclusions with regard to language of Mini-Cog administration or language of publication, using translation services where necessary.

### Selection criteria

We included cross-sectional studies and excluded case-control designs, due to the risk of bias. We selected those studies that included the Mini-Cog as an index test to diagnose dementia where dementia diagnosis was confirmed with reference standard clinical assessment

---

**Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting (Review)**

Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

using standardised dementia diagnostic criteria. We only included studies in secondary care settings (including inpatient and outpatient hospital participants).

### **Data collection and analysis**

We screened all titles and abstracts generated by the electronic database searches. Two review authors independently checked full papers for eligibility and extracted data. We determined quality assessment (risk of bias and applicability) using the QUADAS-2 tool. We extracted data into two-by-two tables to allow calculation of accuracy metrics for individual studies, reporting the sensitivity, specificity, and 95% confidence intervals of these measures, summarising them graphically using forest plots.

### **Main results**

Three studies with a total of 2560 participants fulfilled the inclusion criteria, set in neuropsychology outpatient referrals, outpatients attending a general medicine clinic, and referrals to a memory clinic. Only  $n = 1415$  (55.3%) of participants were included in the analysis to inform evaluation of Mini-Cog test accuracy, due to the selective use of available data by study authors. There were concerns related to high risk of bias with respect to patient selection, and unclear risk of bias and high concerns related to index test conduct and applicability. In all studies, the Mini-Cog was retrospectively derived from historic data sets. No studies included acute general hospital inpatients. The prevalence of dementia ranged from 32.2% to 87.3%. The sensitivities of the Mini-Cog in the individual studies were reported as 0.67 (95% confidence interval (CI) 0.63 to 0.71), 0.60 (95% CI 0.48 to 0.72), and 0.87 (95% CI 0.83 to 0.90). The specificity of the Mini-Cog for each individual study was 0.87 (95% CI 0.81 to 0.92), 0.65 (95% CI 0.57 to 0.73), and 1.00 (95% CI 0.94 to 1.00). We did not perform meta-analysis due to concerns related to risk of bias and heterogeneity.

### **Authors' conclusions**

This review identified only a limited number of diagnostic test accuracy studies using Mini-Cog in secondary care settings. Those identified were at high risk of bias related to patient selection and high concerns related to index test conduct and applicability. The evidence was indirect, as all studies evaluated Mini-Cog differently from the review question, where it was anticipated that studies would conduct Mini-Cog and independently but contemporaneously perform a reference standard assessment to diagnose dementia. The pattern of test accuracy varied across the three studies. Future research should evaluate Mini-Cog as a test in itself, rather than derived from other neuropsychological assessments. There is also a need for evaluation of the feasibility of the Mini-Cog for the diagnosis of dementia to help adequately determine its role in the clinical pathway.

## **PLAIN LANGUAGE SUMMARY**

### **How accurate is the Mini-Cog in detecting dementia among patients in inpatient and outpatient hospital settings?**

#### **Why is recognising dementia important?**

Dementia is a common and important condition, and many of those living with dementia have never had the condition diagnosed. Diagnosis provides opportunities for social support, advance care planning and, in specific disease types, treatment with medication. However, incorrectly diagnosing dementia when it is not present (a false-positive result) can be distressing for the individual and their family and lead to a waste of resources in diagnostic tests.

#### **What was the aim of the review?**

The aim of this Cochrane Review was to find out how accurate the Mini-Cog test is for detecting dementia among patients in inpatient and outpatient hospital settings. The researchers included three studies to answer this question.

#### **What was studied in the review?**

The Mini-Cog is a short test of memory and thinking skills that tests the ability of an individual to remember three specific objects, named at the beginning of a short assessment, repeated at the time and recalled by the individual later. In addition, the individual being assessed is asked to draw a clock face at a specific time. Points are scored based on the ability to recall the three items and the completeness of the clock. The Mini-Cog is a short test that would typically be used to identify if someone was having difficulty with memory and thinking skills who would benefit from referral to a specialist for more detailed assessment.

#### **What are the main results of the review?**

The review included data from three relevant studies with a total of 2560 participants. However, the study authors did not use data from many of those participants they assessed, leaving results from only 1415 participants that provide complete and useful information for addressing the review question.

All three studies scored the Mini-Cog results in the way that was recommended by the developers of the tool. There was no clear pattern in the results of what a positive result of a Mini-Cog test meant across the three studies, making it difficult to draw summary conclusions. Using the studies with the highest and lowest Mini-Cog results indicated that if the Mini-Cog were to be used in secondary care in a group of 1000 people, where 640 (64%) have dementia, an estimated 510 to 557 would have a positive Mini-Cog, of which 0 to 126 would be incorrectly classified as having dementia. Of the 443 to 490 people with a result indicating dementia is not present, 83 to 256 would be incorrectly classified as not having dementia.

**How reliable are the results of the studies in the review?**

In the included studies, the diagnosis of dementia was made by assessing all patients with a detailed clinical assessment. Detailed clinical assessment is the reference standard to which the Mini-Cog was compared. This is likely to have been a reliable method for determining whether patients actually had dementia. However, there were some problems with how the studies were conducted in terms of the people who were included and how the Mini-Cog was calculated, which could result in the Mini-Cog appearing more accurate than it actually is. We decided that it was not appropriate to group the studies together to describe the average performance of the Mini-Cog, due to the differences among them.

**To whom do the results of this review apply?**

The studies included in the review were conducted in the USA, Germany, and Brazil. Two studies included those patients referred to specialists evaluating memory and thinking skills, and one study recruited individuals attending a medical outpatient clinic. The percentage of people with a final diagnosis of dementia was between 32% and 87% (an average of 64%).

**What are the implications of this review?**

The small number of studies identified and variation in how they used the Mini-Cog limit the evidence to make recommendations, and suggest that Mini-Cog may not be the best test to recommend for use in inpatient and outpatient secondary care hospital settings.

**How up-to-date is this review?**

The review authors searched for and considered studies published up to March 2019.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

What is the accuracy of the Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting?				
Population	Adult patients who completed the Mini-Cog, with no restrictions on the case mix of recruited participants			
Setting	Secondary care settings including outpatient clinics, inpatient general, and specialist hospital settings			
Index test	Mini-Cog includes the Clock Draw Tests and 3-word recall			
Reference standard	Clinical diagnosis of dementia using recognised diagnostic criteria			
Studies	Cross-sectional but not case-control studies were included			
Study	Summary accuracy (95% CI)	No. of included participants	Dementia prevalence	Implications, quality, and comments
<a href="#">Clionsky 2010</a> scoring as per <a href="#">Borson 2000</a>	Sensitivity: 0.67 (0.63 to 0.71) Specificity: 0.87 (0.81 to 0.92) Positive PV: 0.94 Negative PV: 0.49	702	73.5%	Only 40% of available records collated from neuropsychology and geriatric psychiatry practice were used to evaluate Mini-Cog accuracy. Sampling frame, inclusion and exclusion criteria were not described. Mini-Cog derived from longer cognitive test battery. Included all-cause dementia and reported dementia subtypes diagnosed Patient selection - high risk of bias; unclear applicability concerns Index test - unclear risk of bias; high applicability concerns Reference standard - low risk of bias; low applicability concerns Flow and timing - high risk of bias
<a href="#">Filho 2009</a> multiple thresholds reported in paper; data quoted with scoring as per <a href="#">Borson 2000</a>	Sensitivity: 0.60 (0.48 to 0.72) Specificity: 0.65 (0.57 to 0.73) Positive PV: 0.45 Negative PV: 0.78	211	32.2%	Multiple exclusion criteria including relying on participants providing informed consent. Only 69% of assessed participants included in the analysis. Focused on those who had 4 or fewer years of education. Mini-Cog derived from longer cognitive

				test battery. Did not report dementia by subtype diagnosed Patient selection - high risk of bias; high applicability concerns Index test - unclear risk of bias; high applicability concerns Reference standard - low risk of bias; low applicability concerns Flow and timing - high risk of bias
<a href="#">Milian 2012</a> scoring as per <a href="#">Borson 2000</a>	Sensitivity: 0.87 (0.83 to 0.90) Specificity: 1.00 (0.94 to 1.00) Positive PV: 1.00 Negative PV: 0.52	502	87.3%	Included individuals admitted to Specialist Memory Clinic setting, but excluded those with depression and mild cognitive impairment which accounts for very high prevalence of dementia. Mini-Cog derived from longer cognitive test battery. Included all-cause dementia and reported dementia subtypes diagnosed Patient selection - high risk of bias; high applicability concerns Index test - unclear risk of bias; high applicability concerns Reference standard - low risk of bias; low applicability concerns Flow and timing - low risk of bias

95% CI: 95% confidence interval  
 Positive PV: positive predictive value  
 Negative PV: negative predictive value

## BACKGROUND

### Target condition being diagnosed

Alzheimer's disease (AD) and related forms of dementia are common among older adults, with a prevalence of 8% in individuals over age 65 years, increasing to a prevalence of approximately 43% in adults aged 85 years and older (Thies 2012). Given the increasing number of older adults in most low and middle income countries, the prevalence of dementia is expected to increase considerably in the coming years (Prince 2016). Currently, an estimated 5.4 million Americans are diagnosed with AD, and this number is expected to increase to 6.7 million by 2025 (Thies 2012). Alzheimer's disease and related forms of dementia are currently incurable and result in considerable direct and indirect costs, both in terms of formal health care and lost productivity from both the affected individual and their caregivers (Thies 2012). There are several potential benefits to diagnosing AD and other dementias early in the disease course. Earlier diagnosis of AD allows for individuals with AD to make decisions regarding future planning whilst they retain the capacity to do so (Prorok 2013). A diagnosis of dementia is also necessary to access certain services and supports for individuals and their caregivers, and pharmacological treatments such as cholinesterase inhibitors or memantine may provide temporary symptomatic improvement in cognitive and functional symptoms for individuals with mild to moderate AD (Birks 2015; Birks 2018; McShane 2019; Rolinski 2012). There has been a relative lack of research exploring whether proactive case-finding for dementia is cost-effective and the impact on those referred for specialist assessment (Robinson 2015).

The diagnosis of AD is clinical and based on a history of decline in cognition with deficits in memory and at least one other area of cognitive functioning (e.g. apraxia, agnosia, or executive dysfunction). There must be a decline from a previous level of functioning that results in significant social or occupational impairment (American Psychiatric Association 2000; McKhann 2001). A definitive diagnosis of AD can only be achieved at autopsy, but a clinical diagnosis using standardised criteria is associated with a sensitivity of 81% and a specificity of 70% when compared to autopsy-proven cases (Knopman 2001).

Approximately 50% to 80% of all individuals with dementia are ultimately classified as AD (Blennow 2006; Brunstrom 2009; Canadian Study of Health and Aging 1994). Whilst individuals with dementias share common characteristics, subtle differences can help to provide a diagnosis in the absence of neuropathological examination. Vascular dementias may occur more abruptly or present with a step-wise decline in cognitive functions over time, and account for approximately 15% to 20% of dementias (Canadian Study of Health and Aging 1994; Feldman 2003; Lobo 2000). Dementia with a mixed vascular and Alzheimer's disease pathology is present in 10% to 30% of cases (Brunstrom 2009; Crystal 2000; Feldman 2003). A smaller proportion of dementias

are associated with dementia with Lewy bodies (Brunstrom 2009, or Parkinson's disease dementia (Aarsland 2005). Individuals experiencing frontotemporal dementia account for a smaller proportion of dementias (4% to 8%) and often present with problems in executive function and changes in behaviour, whilst memory is relatively preserved early in the disease course (Brunstrom 2009; Greicius 2002).

### Index test(s)

The Mini-Cog is a brief cognitive test consisting of two components: a delayed three-word recall and the clock-drawing test (Borson 2000). The Mini-Cog was initially developed in a community setting to provide a relatively brief cognitive screening test that was free of educational and cultural biases (Borson 2000). Different scoring algorithms were tested to determine which combination had the optimal balance of sensitivity and specificity (McCarten 2011; Scanlan 2001). The Mini-Cog takes approximately three to five minutes to complete in routine practice (Borson 2000; Holsinger 2007; Scanlan 2001). The Mini-Cog has been reported to have little potential for bias with education or language (Borson 2000; Borson 2005).

### Clinical pathway

Dementia typically begins with subtle cognitive changes and progresses gradually over the course of several years. There is a presumed period when people are asymptomatic although the disease pathology may be progressing (Ritchie 2015). Individuals or their relatives may first notice subtle impairments of short-term memory or other areas of cognitive functioning. Gradually, the severity of cognitive deficits becomes apparent resulting in difficulty completing complex activities of daily living such as management of finances and medications, or operating motor vehicles (Njegovan 2001; Pérès 2008). The attribution of cognitive symptoms to normal aging may cause delays in the diagnosis and treatment of AD or other types of dementia (Koch 2010). Consequently, there is a need for accurate brief cognitive screening tests to help distinguish between the cognitive changes associated with normal aging and changes that might indicate a dementia.

Cognitive assessment in a secondary care setting occurs in two broad contexts. Either individuals are referred from primary care or community health services for further evaluation of possible memory complaints. Alternatively, individuals may have their cognition evaluated as part of a comprehensive assessment of care needs following an acute, unscheduled hospitalisation. As a consequence, those assessed in secondary care settings would likely have some cognitive complaints or symptoms at the time of evaluation. Previous estimates suggest that 16% of those attending memory clinic had no cognitive impairments (Pusswald 2013), and 62% of hospitalised older adults had no cognitive impairment (Reynish

2017). Secondary care settings that may use the Mini-Cog or other screening tests would include neurology, geriatric medicine, geriatric psychiatry services, or memory clinics. Typically, individuals who are assessed in secondary care settings would receive more detailed neuropsychological testing along with other investigations that are needed in order to confirm a diagnosis of dementia.

### Prior test(s)

Mini-Cog is recommended for use as an initial screening test for dementia, therefore it is unlikely that individuals will have any formal testing completed prior to the administration of the Mini-Cog. The extent of any prior cognitive assessment may vary depending on source of referral (Fisher 2007).

### Role of index test(s)

Most older adults with memory complaints will first present to their general practitioner or other primary healthcare provider (e.g. nurses or a nurse practitioner). Primary healthcare providers may then refer an individual to a secondary care setting such as a neurologist, geriatrician, or geriatric psychiatrist. Some countries have also recommended that brief cognitive screening tests be administered to all older adults in order to help screen for undetected or asymptomatic cognitive impairment (Cordell 2013), although routine screening of older adults for dementia is controversial (Martin 2015). We would anticipate that the Mini-Cog would be utilised as a screening test to guide further evaluation of cognitive complaints for individuals in secondary care and not as a diagnostic test in most instances.

### Alternative test(s)

The Cochrane Dementia and Cognitive Improvement Group (CDCIG) have conducted a series of diagnostic test accuracy reviews of cognitive tests, biomarkers, and informant tools, as a planned programme of reviews (Davis 2013). This review focused only on the test accuracy of Mini-Cog, and alternative tests are not included as they have been examined in separate reviews.

### Rationale

Cognitive diagnostic tests are required to assess cognition and assist in diagnosing conditions such as mild cognitive impairment and dementia. Comprehensive evaluation, conducted by psychologists or dementia specialists such as general psychiatrists, geriatric psychiatrists, geriatricians, or neurologists, using standardised diagnostic criteria, would be the reference standard for assessing cognition and diagnosing dementia in older adults. However, access to these specialised resources is scarce and expensive, and as such they are not practical for routine use in the evaluation of cognitive complaints (Pimlott 2009; Yaffe 2008). Whilst there are some cognitive tests that can be performed by healthcare providers who

are not dementia specialists, many of these tests are time consuming and may not be practical to use as a first-line cognitive screen in secondary care settings. As such, brief but relatively accurate cognitive screening tests are required for healthcare providers in secondary care settings to identify individuals who may require more in-depth evaluation of cognition. In secondary care settings, brief cognitive screening tests may be used to guide subsequent evaluations or to complement more detailed evaluations.

Utilising a standard cognitive screening test like the Mini-Cog also promotes effective communication between healthcare providers. Sensitivity and specificity of such tests vary depending upon the setting in which they are used (Holsinger 2007). Some studies have found that in primary care the majority of older adults with dementia are undiagnosed (Boustani 2005; Sternberg 2000). In addition, many primary care providers have difficulty in accurately diagnosing dementia, and mild dementia in particular is underdiagnosed (van den Dungen 2011). Early diagnosis and treatment of dementia can have clinical benefits for the patient, their community, and the healthcare system (Bennett 2003; Prorok 2013; Thies 2012). Accurate diagnosis of dementia is also important in order to initiate dementia therapeutics including both non-pharmacological treatments and pharmacological treatments such as cholinesterase inhibitors, Birks 2015; Birks 2018; Rolinski 2012, or memantine (McShane 2019). A brief and simple cognitive screening test such as the Mini-Cog that could be used in secondary care settings would allow healthcare professionals or lay people to initially screen older adults for the presence of dementia. Individuals that screen positive for cognitive impairment on the Mini-Cog may then be further investigated for the presence of dementia using additional cognitive tests or other investigations. As Mini-Cog is brief, widely available, easy to administer, and has been reported to have reasonable test accuracy properties (Brodsky 2006; Lin 2013), it may be well suited for use as an initial cognitive screening test in secondary care. The Mini-Cog has been recommended as a suitable cognitive screening test for primary care in some countries (Cordell 2013). The current review examined the diagnostic accuracy of the Mini-Cog in secondary care settings. Separate DTA reviews have been undertaken evaluating the use of Mini-Cog in community and primary care settings (Page 2015; Seitz 2018).

## OBJECTIVES

To determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting.

### Secondary objectives

To investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential

sources of heterogeneity will include the baseline prevalence of dementia in study samples, thresholds used to determine positive test results, the type of dementia (Alzheimer's disease dementia or all causes of dementia), and aspects of study design related to study quality.

We identified gaps in the evidence where further research is required.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included all cross-sectional studies with well-defined populations that utilised the Mini-Cog as an index cognitive screening test compared to a reference standard to identify dementia. Included studies also utilised the Mini-Cog as a screening test and not for confirmation of diagnosis. We excluded case-control studies and longitudinal designs in which there was a gap of more than four weeks between administration of the index test and reference standard.

#### Participants

Study participants were sampled from a secondary care setting and may or may not have ultimately been diagnosed with AD or other dementias. Participants may have had cognitive complaints or dementia at baseline, although their cognitive status should not be known to the individual administering the Mini-Cog or the reference standard. We excluded studies on participants with a developmental disability which prevented them from completing the Mini-Cog. Secondary care settings included inpatient and outpatient hospital participants. We excluded studies including participants in either a community or primary care setting, as these are topics of other reviews (Fage 2015; Seitz 2018).

#### Index tests

##### Mini-Cog test

The Mini-Cog consists of a three-word recall task and the clock-drawing test. The standard scoring system involves assigning a score of zero to three points on the word recall task for the correct recall of 0, 1, 2, or 3 words, respectively. The clock-drawing test is scored as being either 'normal' or 'abnormal'. A positive test on the Mini-Cog (that is dementia) is assigned if either the delayed word recall score is zero out of three, or if the delayed recall score is either one or two, and the clock-drawing test is abnormal. A score

of three on the delayed word recall or one to two on the delayed word recall with a normal clock drawing is a negative test (i.e. is no dementia) (Borson 2000).

Studies had to include the results of the Mini-Cog. Where multiple scoring algorithms were utilised, we explored the differences in results in subgroup analysis. We anticipated that the Mini-Cog would be utilised as a screening test to guide further evaluation of cognitive complaints for individuals in secondary care and not as a diagnostic test in most instances.

#### Target conditions

Target conditions included any stage of AD or other types of dementia including vascular dementia, dementia with Lewy bodies, Parkinson's disease dementia, or frontotemporal dementia.

#### Reference standards

Whilst a definitive diagnosis can only be made postmortem at autopsy, there are clinical criteria for the diagnosis of most forms of dementia. All dementia diagnostic criteria require that an individual has deficits in multiple areas of cognition that results in impairment in daily functioning and is not caused by either the effects of a substance or a general medical condition. We describe potential reference standards for the diagnosis of all-cause dementia or specific types of dementia. All-cause dementia is commonly diagnosed using criteria such as the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) criteria for dementia (American Psychiatric Association 2000), the DSM-5 criteria for major neurocognitive disorder (American Psychiatric Association 2013), or the International Classification of Diseases (ICD) diagnosis of dementia (World Health Organization 2016). The standard clinical diagnostic criteria commonly used for Alzheimer's disease dementia include the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for probable or possible dementia (McKhann 1984; McKhann 2011). Diagnostic criteria for other types of dementia include the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia (Roman 1993), standard criteria for dementia with Lewy bodies (McKeith 2005), and for frontotemporal dementia (McKhann 2001). Evaluation often includes laboratory investigations, many of which are useful for excluding alternative diagnoses (Feldman 2008). Additional procedures to help confirm the diagnosis include specific findings on neuroimaging (either computed tomography (CT) or magnetic resonance imaging (MRI)). These investigations are typically used to confirm the diagnosis rather than rule out the possibility of dementia. Whilst these clinical criteria for dementia are considered the reference standard for the purposes of our review, the sensitivity and specificity of these clinical reference

standards may vary when compared to neuropathological criteria for dementia (Nagy 1998).

## Search methods for identification of studies

### Electronic searches

We searched the Cochrane Dementia Group Register of Diagnostic Test Accuracy Studies, MEDLINE (OvidSP), Embase (OvidSP), BIOSIS Citation Index (ISI Web of Science), Web of Science Core Collection Science Citation Index (ISI Web of Science), PsycINFO (OvidSP), and LILACS (BIREME) (Latin American and Caribbean Health Science Information database). See [Appendix 1](#) for the search strategy used and to view the 'generic' search that is run regularly for the Cochrane Dementia and Cognitive Improvement Group Register of Diagnostic Test Accuracy Studies. Controlled vocabulary such as MeSH terms and Emtree were used where appropriate. In order to maximise sensitivity and allow inclusion on the basis of population-based sampling to be assessed at testing (see [Selection of studies](#)), there was no attempt to restrict studies based on sampling frame or setting in the searches that were developed. We did not use search filters (collections of terms aimed at reducing the number needed to screen) as an overall limiter because those published have not proved sensitive enough (Whiting 2011). We applied no language restriction to the electronic searches, and used translation services as necessary.

A single review author with extensive experience in systematic reviews performed the initial searches (ANS). Two review authors independently screened abstracts and titles.

### Searching other resources

We searched the reference lists of all relevant studies for additional relevant studies. These studies were also used to search the electronic databases to identify additional studies through the use of the related article feature. We asked research groups authoring studies used in the analysis for any unpublished data.

## Data collection and analysis

### Selection of studies

Included studies had to:

1. make use of the Mini-Cog as a cognitive diagnostic tool;
2. include patients from a secondary care setting who may or may not have dementia or cognitive complaints. We did not include case-control studies;
3. clearly explain how a diagnosis of dementia was confirmed according to a reference standard such as the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text

Revision (DSM IV-TR) or NINCDS-ADRDA at the same time or within the same four-week period that the Mini-Cog was administered. Formal neuropsychological evaluation was not required for a diagnosis of dementia.

We first selected articles on the basis of abstracts and titles. We retrieved the full texts of those articles deemed potentially eligible, and two review authors independently assessed these for inclusion in the review. Any disagreements were settled by consulting a third review author.

### Data extraction and management

Two review authors extracted the following data from all included studies.

- Author, journal, and year of publication.
- Scoring algorithm for the Mini-Cog including cut-points used to define a positive screen.
- Method of Mini-Cog administration including who administered and interpreted the test, their training, and whether or not the readers of the Mini-Cog and reference standard were blind (masked) to the results of the other test.
- Reference criteria and method used to confirm diagnosis of AD or other dementias.
- Baseline demographic characteristics of the study population including age, gender, ethnicity, spectrum of presenting symptoms, comorbidity, educational achievement, language, baseline prevalence of dementia, country, apolipoprotein E (*ApoE*) status, methods of participant recruitment, and sampling procedures.
- Length of time between administration of index test (Mini-Cog) and reference standard.
- The true positives, true negatives, false positives, false negatives, disease prevalence, sensitivity and specificity, and positive and negative likelihood ratios of the index test in defining dementia.
- Version of translation (if applicable).
- Prevalence of dementia in the study population.
- Estimates of test reproducibility (if available).

### Assessment of methodological quality

We used the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria to assess data quality (Whiting 2011). The QUADAS-2 criteria contain assessment domains for patient selection, index test, reference test, and flow and timing. Each domain has suggested signalling questions to assist with the 'Risk of bias' assessment for each domain ([Appendix 2](#)). The potential risk of bias associated with each domain is rated as being at high, low, or uncertain risk of bias. In addition, we performed an assessment of the applicability of the study to the review question for each domain using the guide provided in the QUADAS-2. We used a standardised 'Risk of bias' template to extract data on the risk

of bias for each study using the form provided by the UK Support Unit Cochrane Diagnostic Test Accuracy Group ([Appendix 3](#)). We summarised the quality assessment results graphically and presented a narrative summary in the [Results](#).

### Statistical analysis and data synthesis

We performed statistical analysis as per the Cochrane guidelines for diagnostic test accuracy reviews ([Macaskill 2010](#)). Two-by-two tables were constructed separately for the Mini-Cog results for Alzheimer's disease dementia and all-cause dementia where this information was available.

We entered data from the individual studies into Review Manager 5 ([Review Manager 2014](#)). We used reported data on test accuracy and disease prevalence or the true positives (TP), true negatives (TN), false positives (FP), and false negatives (FN), whichever was reported by the individual study. We calculated the sensitivity, specificity, and positive and negative likelihood ratios as well as measures of statistical uncertainty (e.g. 95% confidence intervals). We presented data from each study graphically by plotting sensitivities and specificities on a coupled forest plot.

We did not conduct our prespecified statistical analysis, using bivariate random-effects for meta-analysis due to concerns related to methodological and clinical heterogeneity across the included studies.

### Investigations of heterogeneity

The potential sources of heterogeneity included baseline prevalence of cognitive impairment in the target population, the cut-points used to determine a positive test result, the reference standard used to diagnose dementia, the type of dementia (Alzheimer's disease dementia or all-cause dementia), the severity of dementia in the study sample, and aspects related to study quality. We have presented narrative results where data were available to describe the between-study heterogeneity.

### Sensitivity analyses

We planned to conduct sensitivity analyses to investigate study quality and the impact on overall diagnostic accuracy of Mini-

Cog. We did not perform this analysis given the methodological concerns with all three of the identified studies. We also did not evaluate the impact of individual studies on summary outcome measures, as it was not considered appropriate to calculate a summary measure from the data in the three studies due to their heterogeneity.

### Assessment of reporting bias


We did not investigate reporting bias because of current uncertainty about how it operates in test accuracy studies and the interpretation of existing analytical tools such as funnel plots ([van Enst 2014](#)).

## RESULTS

### Results of the search

The results of the literature search are summarised in [Figure 1](#). An initial review of the electronic databases in September 2012 identified 108 articles. We updated this search in January 2013, adding an additional 106 articles, and completed a second update in February 2015 that identified another 34 potentially relevant citations. The same search strategy was employed for this review that was used in separate reviews of the Mini-Cog in the community setting and the primary care setting ([Fage 2015](#); [Seitz 2018](#)). We performed a final update search for this review only in March 2019, which identified 324 articles. After removal of duplicates, two review authors independently reviewed a total of 468 abstracts and citations to determine those that were potentially eligible. We reviewed a total of 62 full-text articles for eligibility, of which 59 were excluded. Reasons for exclusions were: a lack of a reference standard (N = 20), incorrect setting (N = 14), duplicate publications (N = 12), failure to include the Mini-Cog as an index text (N = 5), wrong study design (N = 4), not using Mini-Cog to diagnose dementia (N = 3), and lack of sufficient data to be included in the review (N = 1). We included three studies in the review.


**Figure 1. Study flow diagram.**



## Methodological quality of included studies

The results of the QUADAS-2 assessment for the three included studies are presented graphically in [Figure 2](#).

**Figure 2. Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study.**



We considered all studies at high risk of bias with respect to patient selection. This was as a result of non-consecutive samples or exclusion of records available for inclusion. There were high applicability concerns with respect to patient selection from two of the studies ([Filho 2009](#); [Milian 2012](#)). These were as a result of excluding those patients with common and important conditions, such as depression or mild cognitive impairment, the exclusion of those with sensory impairments, and the need for some participants to provide informed consent to participate. The inclusion/exclusion criteria for [Clionsky 2010](#) were not reported in the paper, rendering assessment of applicability as at unclear risk. An additional feature common to all the included studies was

the way the index test was performed and evaluated. All studies retrospectively derived the Mini-Cog using responses to the three-word recall and clock-drawing test that were collected as part of a larger and longer battery of neuropsychological tests. The accuracy of the Mini-Cog may have been affected when the result of the Mini-Cog stemmed from more comprehensive testing compared to when the component tests were administered by themselves. As such we rated all studies as at unclear risk of bias for the index test domain and as at high concern regarding the applicability of the results, given that this is not how short cognitive index tests would typically be performed.

In all cases we considered that the reference standard used was

likely to correctly identify the target condition, and the risk of bias associated with this was low and applicability concerns were low. However, there are risks of incorporation bias if the assessments used to derive the Mini-Cog were known to those making the reference standard diagnosis.

We assessed two studies as high risk in the flow and timing domain due to use of multiple reference standards, Clionsky 2010, and selective use of data (Clionsky 2010; Filho 2009). We considered one study as at low risk of bias for the flow and timing domain (Milian 2012).

## Findings

We included three papers in the final review (Clionsky 2010; Filho 2009; Milian 2012). The study population included in the review was 1415 participants. However, this represents only 55.2% of the total population (n = 2560) reported in the included studies. Data from 1145 participants were not available for use (n = 1050 excluded from Clionsky 2010, as only one of their five data sets were included in the analysis for Mini-Cog test accuracy; and n = 95 excluded from Filho 2009 due to incomplete data or having more than four years of formal education, as the study only included those considered to have low levels of education). Clionsky 2010 reported the development and validation of a new cognitive test; this process was based on using historic clinical data sets, and only one of these data sets reported Mini-Cog test accuracy data, thus the majority of participants in the study do not contribute data to this review.

Clionsky 2010 included participants referred to neuropsychology services for assessment; Filho 2009 recruited a selection of participants attending for general medical treatment on an outpatient basis; and Milian 2012 included individuals referred to a memory clinic. None of the studies evaluated Mini-Cog among general hospital inpatients.

Key features of the studies are summarised in the Characteristics of included studies table. Additional features of these studies are also reported in Table 1.


One study did not report dementia subtype, using a binary classi-

fication of dementia versus no dementia (Filho 2009). The other studies reported dementia subtype in more detail, however there was some overlap in the categorisation of subtypes, making direct comparison more challenging (Table 1). Alzheimer's disease was the most common subtype in 57.3%, Clionsky 2010, and 49.1%, Milian 2012, of participants. The prevalence of dementia in the study samples varied from 32.2% (95% confidence interval (CI) 26.3 to 38.8%), Filho 2009, to 87.3% (95% CI 84.1 to 89.9%), Milian 2012, although important exclusions apply to the study populations that impact these figures (e.g. exclusion of those with mild cognitive impairment, depression or any other mental health diagnoses or the need for participants to provide informed consent). The descriptive variables of ethnicity, comorbidity, spectrum of presenting symptoms, and ApoE status were not reported in any of the included studies.

All studies utilised the original scoring system (Borson 2000). Filho 2009 reported multiple thresholds to define Mini-Cog test positivity and the impact of varying the threshold on sensitivity and specificity. Data from the original scoring system are those used to provide comparability between results.

Meta-analysis was planned to determine a summary pooled estimate for the diagnostic test accuracy of Mini-Cog in identifying dementia in secondary care settings. However, due to the methodological limitations and heterogeneity of included studies, we did not perform quantitative synthesis. The extracted data, including sensitivity, specificity, and likelihood ratios for each study, are summarised in Summary of findings. A forest plot is presented in Figure 3. The sensitivities of the Mini-Cog in the individual studies were reported as 0.67 (95% CI 0.63 to 0.71) (Clionsky 2010), 0.60 (95% CI 0.48 to 0.72) (Filho 2009), and 0.87 (95% CI 0.83 to 0.90) (Milian 2012). The specificity of the Mini-Cog for each individual study was 0.87 (95% CI 0.81 to 0.92) (Clionsky 2010), 0.65 (95% CI 0.57 to 0.73) (Filho 2009), and 1.00 (95% CI 0.94 to 1.00) (Milian 2012). Positive predictive values were 0.94 (Clionsky 2010), 0.45 (Filho 2009), and 1.00 (Milian 2012). Negative predictive values were 0.49 (Clionsky 2010), 0.78 (Filho 2009), and 0.52 (Milian 2012).

**Figure 3. Forest plot of individual study results using Mini-Cog in secondary care for the diagnosis of dementia.**



One study reported test accuracy by dementia subtype, classifying these as: all dementia, Alzheimer's dementia, and non-Alzheimer's dementia (Milian 2012). Sensitivity was reported to be higher for Alzheimer's dementia (0.91 versus 0.87) and lower for non-Alzheimer's dementia (0.83 versus 0.87) compared to all dementias, although the authors do not report formal statistical comparisons for these results (Milian 2012).

We did not perform planned subgroup analyses to investigate potential sources of heterogeneity and sensitivity analyses due to the methodological and clinical heterogeneity. Study characteristics regarding prevalence of dementia, cut-points to determine a positive test, the reference standard used to diagnose dementia, and the type of dementia are reported in Table 1. Severity of dementia was not reported in any of the included studies. Study quality is described above and in the Characteristics of included studies table.

## DISCUSSION

### Summary of main results

We found only three studies that evaluated the test accuracy of the Mini-Cog in secondary care settings compared to a reference standard assessment using recognised dementia diagnostic criteria. Only 55.3% of available patient data was used to evaluate the test accuracy of Mini-Cog. Our 'Risk of bias' assessment identified concerns regarding both the internal and external validity of the included studies. In all studies the Mini-Cog was retrospectively derived from historic data sets. No studies included acute general hospital inpatients. The prevalence of dementia ranged from 32.2% to 87.3%. The sensitivities of the Mini-Cog in the individual studies were reported as 0.67 (95% CI 0.63 to 0.71), 0.60 (95% CI 0.48 to 0.72), and 0.87 (95% CI 0.83 to 0.90). The specificity of the Mini-Cog for each individual study was 0.87 (95% CI 0.81 to 0.92), 0.65 (95% CI 0.57 to 0.73), and 1.00 (95% CI 0.94 to 1.00). Positive predictive values were 0.94, 0.45, and 1.00. Negative predictive values were 0.49, 0.78, and 0.52. We did not perform meta-analysis due to the concerns regarding risk of bias and heterogeneity.

### Strengths and weaknesses of the review

We conducted the review following the published protocol (Chan 2014), with only limited differences (Differences between protocol and review). The search strategy was robust and conducted by an Information Specialist, using an approach common across the Mini-Cog reviews. Study quality was formally evaluated using the QUADAS-2 methodology (Appendix 2) and utilising anchoring statements common across the Cochrane Dementia and Cognitive Improvement Group suite of diagnostic test accuracy reviews (Appendix 3).

Limitations of the review primarily reflect the lack of eligible studies for inclusion and heterogeneity of populations and methods. These precluded the conduct of the prespecified analyses, including evaluating dementia subtype and producing a summary of test estimate Mini-Cog test accuracy in secondary care and more detailed evaluation of the effect of heterogeneity on study findings. We recognise that had the identified studies been more methodologically and clinically consistent, specific methods have been developed to allow meta-analysis of diagnostic test accuracy studies when there are small numbers of studies identified for inclusion (Takwoingi 2017). Finally, in common with other diagnostic test accuracy reviews in dementia, the reliance on an imperfect reference standard is an important limitation to acknowledge.

### Applicability of findings to the review question

This review sought to evaluate the test accuracy of the Mini-Cog for detecting dementia in secondary care. None of the included studies evaluated the Mini-Cog as a traditional test accuracy approach would anticipate: where the Mini-Cog would be conducted and this would be followed by an independent and contemporaneous reference standard assessment to diagnose dementia. All three studies retrospectively derived Mini-Cog from more lengthy neuropsychological tests, which had the potential to introduce bias. There is also potential for incorporation bias within the reference standard, as the components of these tests may have helped inform reference standard assessment. Finally, the three populations studied are non-consecutive with exclusions which affect the prevalence of dementia and applicability of results to current clinical practice. As such, evaluation of the included studies make it difficult to answer the question underpinning this review.

## AUTHORS' CONCLUSIONS

### Implications for practice

The available studies have not considered use of Mini-Cog as a stand-alone cognitive assessment compared to reference standard diagnosis of dementia. The methodological limitations and heterogeneity, coupled with the small number of included studies, means there is limited information to draw firm conclusions. The results are inconsistent with respect to the pattern of test accuracy. The currently available evidence thus does not support recommending Mini-Cog as a short cognitive test for use in secondary care settings. This finding is in-keeping with the evidence regarding use of Mini-Cog in primary care, Seitz 2018, and community settings, Fage 2015. A range of brief cognitive tests are available and used in clinical practice (Velayudhan 2014), although with a lack of empirical head-to-head data comparing their test accuracy. Other cognitive tests, such as the Montreal Cognitive Assessment, Davis 2015, or Mini-Mental State Examination, Creavin 2016,

appear to have higher levels of sensitivity 0.94 (no 95% confidence interval (CI) reported) and 0.85 (95% CI 0.74 to 0.92) respectively, which may be desirable in a screening test. However, the greater burden of testing associated with longer instruments needs to be taken into account.

## Implications for research

Future research should specifically evaluate the Mini-Cog as an index test, rather than as part of a wider cognitive test battery, or when authors are attempting to create a new diagnostic instrument. Use of multiple different instruments and creation of new tools is common across the dementia and cognitive impairment literature, and potentially represents a barrier to research due to lack of standardisation and heterogeneity of assessment (Harrison 2016).

Furthermore, the included studies did not address any feasibility questions around use of Mini-Cog. Some studies specifically excluded those with sensory impairment or hand movement limitations. Mini-Cog is a short cognitive test and thus may show promise with respect to feasibility in practice. The ability of hospitalised adult populations to complete diagnostic assessments is

a critical part of determining the applicability and usefulness of a testing strategy in clinical practice and one that has been commonly overlooked in the dementia diagnostic test accuracy literature in secondary care (Elliott 2019; Harrison 2015; Lees 2017).

Authors conducting diagnostic test accuracy research in the dementia field should utilise reporting guidance to help improve transparency and allow a more complete critical evaluation of the methodology employed (Noel-Storr 2014).

Finally, the aim of evaluating the test accuracy of tools to identify dementia is to improve diagnostic pathways to achieve better outcomes for individuals using health and care services. Further research is needed to evaluate the role of diagnostic strategies in changing individual and population-level outcomes to ensure that use of instruments is appropriate.

## ACKNOWLEDGEMENTS

We would like to thank peer reviewers Tom Dening and Andrew Larner and consumer reviewer Cathie Hofstetter for their comments and feedback.

## REFERENCES

### References to studies included in this review

#### Clionsky 2010 *{published data only}*

Clionsky MI, Clionsky E. Development and validation of the memory orientation screening test (MOST): a better screening test for dementia. *American Journal of Alzheimer's Disease & Other Dementias* 2010;**25**:650–6.

#### Filho 2009 *{published data only}*

Filho STR, Lourenco RA. The performance of the Mini-Cog in a sample of low educational level elderly [O desempenho do Mini-Cog em uma amostra de idosos com baixo nível educacional]. *Dementia & Neuropsychologia* 2009;**3**:81–7.

#### Milian 2012 *{published data only}*

Milian M, Leiherr AM, Straten G, Muller S, Leyhe T, Eschweiler GW. The Mini-Cog versus the Mini-Mental State Examination and the Clock Drawing Test in daily clinical practice: screening value in a German Memory Clinic. *International Psychogeriatrics* 2012;**24**:766–74.

### References to studies excluded from this review

#### Borson 2000 *{published data only}*

Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The Mini-Cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. *International Journal of Geriatric Psychiatry* 2000;**15**(11):1021–7.

#### Borson 2003 *{published data only}*

Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. *Journal of the American Geriatrics Society* 2003;**51**:1451–4.

#### Borson 2005 *{published data only}*

Borson S, Scanlan J, Watanabe J, Tu S-P, Lessig M. Simplifying detection of cognitive impairment: comparison of the Mini-Cog and Mini-Mental State Examination in a multiethnic sample. *Journal of the American Geriatrics Society* 2005;**53**:871–4.

#### Borson 2006 *{published data only}*

Borson S, Scanlan JM, Watanabe J, Tu SP, Lessig M. Improving identification of cognitive impairment in primary care. *International Journal of Geriatric Psychiatry* 2006;**21**:349–55.

#### Carnero-Pardo 2013 *{published data only}*

Carnero-Pardo C, Cruz-Orduña I, Espejo-Martínez B, Martos-Aparicio C, López-Alcalde S, Olazarán J. Utility of the Mini-Cog for detection of cognitive impairment in primary care: data from two Spanish studies. *International Journal of Alzheimer's Disease* 2013;**2013**:285462.

#### Carnero-Pardo 2019 *{published data only}*

Carnero-Pardo C, Rego-García I, Barrios-López JM, Blanco-Madera S, Calle-Calle R, López-Alcalde S, et al. Assessment of the diagnostic accuracy and discriminative validity of the Clock Drawing and Mini-Cog tests in

- detecting cognitive impairment. *Neurologia* 2019;pii: S0213-4853(19)30008-8.
- Chen 2011** *{published data only}*  
Chen CY, Leung KK, Chen CY. A quick dementia screening tool for primary care physicians. *Archives of Gerontology and Geriatrics* 2011;**53**:100-3.
- Dash 2004** *{published data only}*  
Dash P, Troupin A, Thomsen J, Knowlton M. The Q&E is more sensitive than Clock Draw, Mini-Cog, and Six-Item Screener in the detection of mild dementia. *Annals of Neurology* 2004;**56**:S19.
- Del Ser 2000** *{published data only}*  
Del Ser T, McKeith I, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Dementia with Lewy Bodies: findings from an international multicentre study. *International Journal of Geriatric Psychiatry* 2000;**15**:1034-45.
- Dougherty 2010** *{published data only}*  
Dougherty JH Jr, Cannon RL, Nicholas CR, Hall L, Hare F, Carr E, et al. The Computerized Self Test (CST): an interactive, internet accessible cognitive screening test for dementia. *Journal of Alzheimer's Disease* 2010;**20**:185-95.
- Fuchs 2012** *{published data only}*  
Fuchs A, Wiese B, Altiner A, Wollny A, Pentzek M. Cued recall and other cognitive tasks to facilitate dementia recognition in primary care. *Journal of the American Geriatrics Society* 2012;**60**:130-5.
- Geschke 2019** *{published data only}*  
Geschke K, Weyer-Elberich V, Mueller AK, Binder H, Fellgiebel A. Feasibility and utility of a cognitive screening for risk stratification in hospitalized older patients. *International Journal of Geriatric Psychiatry* 2019;**34**(4): 588-93.
- Holsinger 2012** *{published data only}*  
Holsinger T, Plassman BL, Stechuchak KM, Burke JR, Coffman CJ, Williams JW Jr. Screening for cognitive impairment: comparing the performance of four instruments in primary care. *Journal of the American Geriatrics Society* 2012;**60**:1027-36.
- McCarten 2012** *{published data only}*  
McCarten JR, Anderson P, Kuskowski MA, McPherson SE, Borson S, Dysken MW. Finding dementia in primary care: the results of a clinical demonstration project. *Journal of the American Geriatrics Society* 2012;**60**:210-17.
- Milian 2013** *{published data only}*  
Milian M, Leiherr AM, Straten G, Müller S, Leyhe T, Eschweiler GW. The Mini-Cog, Clock Drawing Test, and the Mini-Mental State Examination in a German Memory Clinic: specificity of separation dementia from depression. *International Psychogeriatrics* 2013;**25**(1):96-104.
- Sonnett 2012** *{published data only}*  
Sonnett TE, Setter SM, Weeks DL, Borson S. Point-of-care screening to identify cognitive impairment in older adults. *Journal of the American Pharmacists Association* 2012;**52**(4): 492-7.
- Steenland 2008** *{published data only}*  
Steenland NK, Auman CM, Patel PM, Bartell SM, Goldstein FC, Levey AI, et al. Development of a rapid screening instrument for mild cognitive impairment and undiagnosed dementia. *Journal of Alzheimer's Disease* 2008;**15**:419-27.
- Wilber 2005** *{published data only}*  
Wilber ST, Lofgren SD, Mager TG, Blanda M, Gerson LW. An evaluation of two screening tools for cognitive impairment in older emergency department patients. *Academic Emergency Medicine* 2005;**12**(7):612-6.
- Wright 2011** *{published data only}*  
Wright DW, Navarez H, Kilgo P, Laplaca M, Robinson A, Fowler S, et al. A novel technology to screen for cognitive impairment in the elderly. *American Journal of Alzheimer's Disease and Other Dementias* 2011;**26**(6):484-91.
- Yang 2016** *{published data only}*  
Yang L, Yan J, Jin X, Jin Y, Yu W, Xu S, et al. Screening for dementia in older adults: comparison of Mini-Mental State Examination, Mini-Cog, Clock Drawing Test and AD8. *PLOS ONE* 2016;**11**(12):e0168949.
- Yang 2018** *{published data only}*  
Yang L, Yan J, Jin X, Jin Y, Yu W, Xu S, et al. Estimation of diagnostic performance of dementia screening tests: Mini-Mental State Examination, Mini-Cog, Clock Drawing test and Ascertain Dementia 8 questionnaire. *Aging & Mental Health* 2018;**22**(8):942-6.

## Additional references

- Aarsland 2005**  
Aarsland D, Zaccari J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. *Movement Disorders* 2005;**20**:1255-63.
- American Psychiatric Association 2000**  
American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th Edition. Washington, DC: American Psychiatric Association, 2000.
- American Psychiatric Association 2013**  
American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 5th Edition. Washington, DC: American Psychiatric Association, 2013.
- Bennett 2003**  
Bennett P, Leifer MD. Early diagnosis of Alzheimer's disease: clinical and economic benefits. *Journal of the American Geriatrics Society* 2003;**51**(1):S281-8.
- Birks 2015**  
Birks JS, Chong LY, Grimley Evans J. Rivastigmine for Alzheimer's disease. *Cochrane Database of Systematic Reviews* 2015, Issue 9. DOI: 10.1002/14651858.CD001191.pub3
- Birks 2018**  
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database of Systematic Reviews* 2018, Issue 6. DOI: 10.1002/14651858.CD001190.pub3
- Blennow 2006**  
Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. *Lancet* 2006;**368**:387-403.

**Boustani 2005**

Boustani M, Callahan CM, Unverzagt FW, Austrom MG, Perkins AJ, Fultz BA, et al. Implementing a screening and diagnosis program for dementia in primary care. *Journal of General Internal Medicine* 2005;**20**:572–7.

**Brodaty 2006**

Brodaty H, Lee-Fay L, Gibson L, Burns K. What is the best dementia screening instrument for general practitioners to use?. *American Journal of Geriatric Psychiatry* 2006;**14**:391–400.

**Brunnstrom 2009**

Brunnstrom H, Gustafson L, Passant U, Englund E. Prevalence of dementia subtypes: a 30-year retrospective study of neuropathological reports. *Archives of Gerontology and Geriatrics* 2009;**49**:146–9.

**Canadian Study of Health and Aging 1994**

Canadian Study of Health and Aging. Canadian study of health and aging: study methods and prevalence of dementia. *CMAJ* 1994;**150**:899–913.

**Chan 2014**

Chan CCH, Fage BA, Smailagic N, Gill SS, Herrmann N, Nikolaou V, et al. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. *Cochrane Database of Systematic Reviews* 2014, Issue 12. DOI: 10.1002/14651858.CD011414

**Cordell 2013**

Cordell CB, Borson S, Chodosh J, Reuben D, Verghese J, Thies W, et al. Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. *Alzheimer's & Dementia* 2013;**9**:141–50.

**Creavin 2016**

Creavin ST, Wisniewski S, Noel-Storr AH, Trevelyan CM, Hampton T, Rayment D, et al. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. *Cochrane Database of Systematic Reviews* 2016, Issue 1. DOI: 10.1002/14651858.CD011145

**Crystal 2000**

Crystal HA, Dickson D, Davies P, Masur D, Grober E, Lipton RB. The relative frequency of "dementia of unknown etiology" increases with age and is nearly 50% in nonagenarians. *Archives of Neurology* 2000;**57**:713–9.

**Davis 2013**

Davis DHJ, Creavin ST, Noel-Storr A, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementia: a generic protocol for cross-sectional and delayed-verification studies. *Cochrane Database of Systematic Reviews* 2013, Issue 3. DOI: 10.1002/14651858.CD010460

**Davis 2015**

Davis DHJ, Creavin ST, Yip JLY, Noel-Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias.

*Cochrane Database of Systematic Reviews* 2015, Issue 10. DOI: 10.1002/14651858.CD010775.pub2

**Elliott 2019**

Elliott E, Drozdowska BA, Taylor-Rowan M, Shaw RC, Cuthbertson C, Quinn TJ. Who is classified as untestable on brief cognitive screens in an acute stroke setting?. *Diagnostics* 2019;**9**(3):E95.

**Fage 2015**

Fage BA, Chan CC, Gill SS, Noel-Storr AH, Herrmann N, Smailagic N, et al. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community setting. *Cochrane Database of Systematic Reviews* 2015, Issue 2: CD010860. DOI: 10.1002/14651858.CD010860.pub2

**Feldman 2003**

Feldman H, Levey AR, Hsiung GY, Peters KR, Donald A, Black SE, et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. *Neuroepidemiology* 2003;**22**(5):265–74.

**Feldman 2008**

Feldman H, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, et al. Diagnosis and treatment of dementia: 2. Diagnosis. *CMAJ* 2008;**178**(7):825–36.

**Fisher 2007**

Fisher CAH, Lerner AJ. Frequency and diagnostic utility of cognitive test instrument use by GPs prior to memory clinic referral. *Family Practice* 2007;**24**(5):495–7.

**Greicius 2002**

Greicius MD, Geschwind MD, Miller BL. Presenile dementia syndromes: an update on taxonomy and diagnosis. *Journal of Neurology, Neurosurgery, and Psychiatry* 2002;**72**:691–700.

**Harrison 2015**

Harrison JK, Fearon P, Noel-Storr AH, McShane R, Stott DJ, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis of dementia within a secondary care setting. *Cochrane Database of Systematic Reviews* 2015, Issue 3. DOI: 10.1002/14651858.CD010772

**Harrison 2016**

Harrison JK, Noel-Storr AH, Demeyere N, Reynish EL, Quinn TJ. Outcome measures in a decade of dementia and mild cognitive impairment trials. *Alzheimer's Research & Therapy* 2016;**8**:48.

**Holsinger 2007**

Holsinger T, Deveau J, Boustani M, Williams J. Does this patient have dementia?. *JAMA* 2007;**297**(21):2391–404.

**Knopman 2001**

Knopman D, DeKosky S, Cummings J, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: Diagnosis of dementia (an evidence-based review). *Neurology* 2001;**56**:1143–53.

**Koch 2010**

Koch T, Iliffe S, and the EVIDEM-ED project. Rapid appraisal of barriers to the diagnosis and management of

patients with dementia in primary care: a systematic review. *BMC Family Practice* 2010;**11**:52.

#### Lees 2017

Lees RA, Hendry Ba K, Broomfield N, Stott D, Lerner AJ, Quinn TJ. Cognitive assessment in stroke: feasibility and test properties using differing approaches to scoring of incomplete items. *International Journal of Geriatric Psychiatry* 2017;**32**(10):1072–8.

#### Lin 2013

Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force. *Annals of Internal Medicine* 2013;**159**:601–12.

#### Lobo 2000

Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. *Neurology* 2000;**54 Suppl 5**:S4–9.

#### Macaskill 2010

Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Chapter 10: Analysing and presenting results. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy*. Version 1.0. The Cochrane Collaboration, 2010. Available from: <http://srdta.cochrane.org/>. The Cochrane Collaboration.

#### Martin 2015

Martin S, Kelly S, Khan A, Cullum S, Denning T, Rait G, et al. Attitudes and preferences towards screening for dementia: a systematic review of the literature. *BMC Geriatrics* 2015;**15**:66.

#### McCarten 2011

McCarten JR, Anderson P, Kuskowski MA, McPherson SE, Borson S. Screening for cognitive impairment in an elderly veteran population: acceptability and results using different versions of the Mini-Cog. *Journal of the American Geriatrics Society* 2011;**59**:309–13.

#### McKeith 2005

McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology* 2005;**65**:1863–72.

#### McKhann 1984

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease. *Neurology* 1984;**34**:939–44.

#### McKhann 2001

McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, et al. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Archives of Neurology* 2001;**58**:1803–9.

#### McKhann 2011

McKhann G, Knopman D, Chertkow H, Hyman B, Jack C, Kawas C, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National

Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & Dementia* 2011;**7**:263–9.

#### McShane 2019

McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. *Cochrane Database of Systematic Reviews* 2019, Issue 3. DOI: 10.1002/14651858.CD003154.pub6

#### Nagy 1998

Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EMF, et al. Accuracy of clinical operational diagnostic criteria for Alzheimer's disease in relation to different pathological diagnostic protocols. *Dementia and Geriatric Cognitive Disorders* 1998;**9**:219–26.

#### Njegovan 2001

Njegovan V, Man-Song-Hing M, Mitchell SL, Molnar F. The hierarchy of functional loss associated with cognitive decline in older persons. *Journals of Gerontology: Medical Sciences* 2001;**56A**:M638–43.

#### Noel-Storr 2014

Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, et al. Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative. *Neurology* 2014;**83**(4):364–73.

#### Pimlott 2009

Pimlott NJ, Persaud M, Drummond N, Cohen CA, Silvius JL, Seigel K, et al. Family physicians and dementia in Canada: Part 1. Clinical practice guidelines: awareness, attitudes and opinions. *Canadian Family Physician* 2009;**55**:508–9.

#### Prince 2016

Prince M, Ali G-C, Guerchet M, Prina M, Albanese E, Wu Y-T. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. *Alzheimer's Research & Therapy* 2016;**8**:23.

#### Prorok 2013

Prorok JC, Horgan S, Seitz DP. Health care experiences of people with dementia and their caregivers: a meta-ethnographic analysis of qualitative studies. *CMAJ* 2013;**185**:E669–880.

#### Pusswald 2013

Pusswald G, Mosler D, Gleiss A, Janzek-Hawlat S, Auff E, Dal-Bianco P, et al. Prevalence of mild cognitive impairment subtypes in patients attending a memory outpatient clinic - comparison of two modes of mild cognitive impairment classification. Results of the Vienna Conversion to Dementia Study. *Alzheimer's & Dementia* 2013;**9**(4):366–76.

#### Péres 2008

Péres K, Helmer C, Amieva H, Orgogozo JM, Rouch I, Dartigues JF, et al. Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. *Journal of the American Geriatrics Society* 2008;**56**(1):37–44.

**Review Manager 2014 [Computer program]**

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan) Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

**Reynish 2017**

Reynish EL, Hapca SM, De Souza N, Cvoro V, Donnan PT, Guthrie B. Epidemiology and outcomes of people with dementia, delirium, and unspecified cognitive impairment in the general hospital: prospective cohort study of 10,014 admissions. *BMC Medicine* 2017;**15**:140.

**Ritchie 2015**

Ritchie CW, Terrera GM, Quinn TJ. Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research. *Alzheimer's Research & Therapy* 2015;**7**:31.

**Robinson 2015**

Robinson L, Tang E, Taylor J-P. Dementia: timely diagnosis and early intervention. *BMJ* 2015;**350**:h3029.

**Rolinski 2012**

Rolinski I, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. *Cochrane Database of Systematic Reviews* 2012, Issue 2. DOI: 10.1002/14651858.CD006504.pub2

**Roman 1993**

Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. *Neurology* 1993;**43**:250–60.

**Scanlan 2001**

Scanlan J, Borson S. The Mini-Cog: receiver operating characteristics with expert and naive raters. *International Journal of Geriatric Psychiatry* 2001;**16**:216–22.

**Seitz 2018**

Seitz DP, Chan CC, Newton HT, Gill SS, Herrmann N, Smailagic N, et al. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a primary care setting. *Cochrane Database of Systematic Reviews* 2018, Issue 2. DOI: 10.1002/14651858.CD011415.pub2

**Sternberg 2000**

Sternberg SA, Wolfson C, Baumgarten M. Undetected dementia in community-dwelling older people: The

Canadian Study of Health and Aging. *Journal of the American Geriatrics Society* 2000;**40**(11):1430–4.

**Takwoingi 2017**

Takwoingi Y, Guo B, Riley RD, Deeks JJ. Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. *Statistical Methods in Medical Research* 2017;**26**(4):1896–1911.

**Thies 2012**

Thies W, Bleiler L. 2012 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* 2012;**8**:131–68.

**van den Dungen 2011**

van den Dungen P, van Marwijk H, van der Horst H, van Charante E, Vroomen J, van de Ven P, et al. The accuracy of family physicians' dementia diagnoses at different stages of dementia: a systematic review. *International Journal of Geriatric Psychiatry* 2011;**27**:342–54.

**van Enst 2014**

van Enst WA, Ochodo E, Scholten RJ, Hooft L, Leeflang MM. Investigation of publication bias in meta-analyses of diagnostic test accuracy: a meta-epidemiological study. *BMC Medical Research Methodology* 2014;**14**:70.

**Velayudhan 2014**

Velayudhan L, Ryu SH, Raczek M, Philpot M, Lindesay J, Critchfield M, et al. Review of brief cognitive tests for patients with suspected dementia. *International Psychogeriatrics* 2014;**26**(8):1247–62.

**Whiting 2011**

Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. *Annals of Internal Medicine* 2011;**155**(8):529–36.

**World Health Organization 2016**

World Health Organization. International Statistical Classification of Diseases and related Health Problems. <https://icd.who.int/browse10/2016/en>.

**Yaffe 2008**

Yaffe MJ, Orzeck P, Barylak L. Family physicians' perspectives on care of dementia patients and family caregivers. *Canadian Family Physician* 2008;**54**:1008–15.

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies *[ordered by study ID]*

#### Clionsky 2010

Study characteristics			
Patient sampling	The study had access to 1752 patient records collated from 5 data sources from neuropsychology and geriatric psychiatry practice. Sampling frame for record collection is not described. 702 records collected between 2005 and 2008 were used to generate data evaluating Mini-Cog test accuracy		
Patient characteristics and setting	Records used in the analysis were collected in a neuropsychology setting where individuals were referred by a physician or agency in the community. No inclusion or exclusion criteria are listed		
Index tests	Mini-Cog was retrospectively derived from results of the Mini-Mental State Examination (which contains 3-item recall) and Clock Draw Test, so the index test was not conducted contemporaneously as expected in the review question. Mini-Cog was scored according to original criteria in <a href="#">Borson 2000</a> .		
Target condition and reference standard(s)	Clinical diagnosis of dementia was determined based on DSM-IV criteria by 1 of 6 licenced psychologists. Patients were evaluated based on their age- and education-adjusted neuropsychological test scores, medical and psychiatric history, and interview with a family informant		
Flow and timing	Study authors made use of 5 data sets to perform the retrospective analyses reported in the paper. Those in neuropsychology received a different reference standard assessment to those assessed in geriatric psychiatry. Reason for use of only 1 set of individuals assessed in neuropsychology for calculation of test accuracy results not provided in the paper		
Comparative			
Notes			
Methodological quality			
Item	Authors' judgement	Risk of bias	Applicability concerns
DOMAIN 1: Patient Selection			
Was a consecutive or random sample of patients enrolled?	No		
Was a case-control design avoided?	Yes		
Did the study avoid inappropriate exclusions?	Unclear		
		High	Unclear

<b>DOMAIN 2: Index Test All tests</b>			
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-specified?	Yes		
		<b>Unclear</b>	<b>High</b>
<b>DOMAIN 3: Reference Standard</b>			
Is the reference standards likely to correctly classify the target condition?	Yes		
Were the reference standard results interpreted without knowledge of the results of the index tests?	Yes		
		<b>Low</b>	<b>Low</b>
<b>DOMAIN 4: Flow and Timing</b>			
Was there an appropriate interval between index test and reference standard?	Yes		
Did all patients receive the same reference standard?	No		
Were all patients included in the analysis?	No		
		<b>High</b>	

**Filho 2009**

<b>Study characteristics</b>	
Patient sampling	Convenience sample of 306 recruited individuals, 65 years of age or older, seeking general medical treatment as outpatients at Internal Medicine Clinic of the Policlínica Piquet Carneiro at Rio de Janeiro State University Hospital. Sampling limited by the number of consenting individuals and availability of research team to assess individuals each day. Occasionally, patients returned next day to finish their testing. Final sample restricted only to those 211 individuals who had complete

	assessment data and 4 or fewer years of schooling
Patient characteristics and setting	Inclusion criteria included preserved hearing and comprehension to fully participate in the study and sign an informed consent form. Exclusions were reports of a serious uncorrected visual or auditory deficiency; being at an advanced stage of cognitive disturbance or having any mental illness that could compromise understanding of and performance on the test procedures; having a native language other than Portuguese; and difficulty in hand movement due to rheumatic or neurological diseases
Index tests	Multiple thresholds for defining a positive result using Mini-Cog are reported in the paper. These include the methodology described by Borson 2000. Mini-Cog was not collected at the time of patient assessment but derived retrospectively, so the index test was not conducted contemporaneously as expected in the review question
Target condition and reference standard(s)	The diagnosis of dementia was made based on the formal criteria of DSM-IV, as agreed upon between geriatrician and neuropsychologist. This included clinical impression and neuropsychological evaluation, including some components of the index tests
Flow and timing	Neuropsychological assessments could be administered on different days. Patients who were lost in follow-up and those who did not finish their evaluation were excluded. Those with more than 4 years of education were excluded from the analysis despite being assessed
Comparative	
Notes	

**Methodological quality**

Item	Authors' judgement	Risk of bias	Applicability concerns
<b>DOMAIN 1: Patient Selection</b>			
Was a consecutive or random sample of patients enrolled?	No		
Was a case-control design avoided?	Yes		
Did the study avoid inappropriate exclusions?	No		
		<b>High</b>	<b>High</b>
<b>DOMAIN 2: Index Test All tests</b>			
Were the index test results interpreted without knowledge of the results of the reference standard?	Yes		

**Filho 2009** (Continued)

If a threshold was used, was it pre-specified?	Unclear		
		Unclear	High
<b>DOMAIN 3: Reference Standard</b>			
Is the reference standards likely to correctly classify the target condition?	Yes		
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear		
		Low	Low
<b>DOMAIN 4: Flow and Timing</b>			
Was there an appropriate interval between index test and reference standard?	Yes		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	No		
		High	

**Milian 2012**

<b>Study characteristics</b>	
Patient sampling	Participants selected retrospectively from all admitted patients to the Memory Clinic of the Department of Psychiatry and Psychotherapy of the University Hospital of Tübingen between 2004 to 2009. Sampling frame is not described, but non-consecutive sample included based on exclusion criteria
Patient characteristics and setting	Sample composed of older adults with normal or corrected-to-normal visual acuity, “sufficient hearing ability”, and a wide education range. Those described as having “severe handicap affecting the ability to perform the required tasks”, mild cognitive impairment, or a depressive episode were excluded from analysis in the study. Also, patients with underlying neurological and psychiatric disorder unrelated to the diagnosis of dementia were excluded. Study was set in an inpatient memory clinic in Germany of individuals referred for evaluation of cognition

Index tests	Study participants completed the clock-drawing test and Mini-Mental State Examination (which contains 3-item recall) as part of their assessment. This was done without knowledge of reference standard diagnosis. However, the full index test (Mini-Cog) was retrospectively derived, so the index test was not conducted contemporaneously as expected in the review question. Mini-Cog results were scored in accordance with original scoring guidance from tool authors (Borson 2000).		
Target condition and reference standard(s)	Clinical diagnosis of dementia based on DSM-IV criteria, the ICD-10 of Mental and Behavioural Disorders, and NINCDS-ADRDA. Index test results (from Mini-Cog) were not calculated at the time of reference standard diagnosis. Other neuropsychological tests results were available and informed reference standard diagnosis		
Flow and timing	Information to inform the index test and reference standard was collected contemporaneously as part of a diagnostic assessment. The items used to derive the index test were collected prior to completion of a reference standard diagnosis		
Comparative			
Notes			
<b>Methodological quality</b>			
<b>Item</b>	<b>Authors' judgement</b>	<b>Risk of bias</b>	<b>Applicability concerns</b>
<b>DOMAIN 1: Patient Selection</b>			
Was a consecutive or random sample of patients enrolled?	No		
Was a case-control design avoided?	Yes		
Did the study avoid inappropriate exclusions?	No		
		<b>High</b>	<b>High</b>
<b>DOMAIN 2: Index Test All tests</b>			
Were the index test results interpreted without knowledge of the results of the reference standard?	Unclear		
If a threshold was used, was it pre-specified?	Yes		
		<b>Unclear</b>	<b>High</b>

<b>DOMAIN 3: Reference Standard</b>			
Is the reference standards likely to correctly classify the target condition?	Yes		
Were the reference standard results interpreted without knowledge of the results of the index tests?	Unclear		
		<b>Low</b>	<b>Low</b>
<b>DOMAIN 4: Flow and Timing</b>			
Was there an appropriate interval between index test and reference standard?	Yes		
Did all patients receive the same reference standard?	Yes		
Were all patients included in the analysis?	Yes		
		<b>Low</b>	

DSM-IV - Diagnostic and Statistical Manual of Mental Disorders, fourth edition; ICD-10 - International Classification of Diseases, Tenth Revision; NINCDS-ADRDA - National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association

**Characteristics of excluded studies [ordered by study ID]**

Study	Reason for exclusion
<a href="#">Borson 2000</a>	Wrong setting - not in secondary care
<a href="#">Borson 2003</a>	Wrong setting - not in secondary care
<a href="#">Borson 2005</a>	Wrong setting - not in secondary care
<a href="#">Borson 2006</a>	Wrong setting - not in secondary care
<a href="#">Carnero-Pardo 2013</a>	Wrong setting - not in secondary care

(Continued)

<a href="#">Carnero-Pardo 2019</a>	Wrong outcome measure - not diagnosing dementia
<a href="#">Chen 2011</a>	Participants did not receive gold standard evaluation using standardised diagnostic criteria
<a href="#">Dash 2004</a>	Participants did not receive gold standard evaluation using standardised diagnostic criteria
<a href="#">Del Ser 2000</a>	Study did not use Mini-Cog as index test.
<a href="#">Dougherty 2010</a>	Wrong study design
<a href="#">Fuchs 2012</a>	Wrong setting - not in secondary care
<a href="#">Geschke 2019</a>	Participants did not receive gold standard evaluation using standardised diagnostic criteria
<a href="#">Holsinger 2012</a>	Wrong setting - not in secondary care
<a href="#">McCarten 2012</a>	Wrong setting - not in secondary care
<a href="#">Milian 2013</a>	Duplicate publication/data
<a href="#">Sonnnett 2012</a>	Participants did not receive gold standard evaluation using standardised diagnostic criteria
<a href="#">Steenland 2008</a>	Wrong study design
<a href="#">Wilber 2005</a>	Participants did not receive gold standard evaluation using standardised diagnostic criteria
<a href="#">Wright 2011</a>	Study did not use Mini-Cog as index test.
<a href="#">Yang 2016</a>	Wrong setting - not in secondary care
<a href="#">Yang 2018</a>	Wrong setting - not in secondary care

## DATA

Presented below are all the data for all of the tests entered into the review.


### Tests. Data tables by test

Test	No. of studies	No. of participants
<a href="#">1 Mini-Cog in secondary care</a>	3	1415

#### Test 1. Mini-Cog in secondary care.

Review: Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting

Test: 1 Mini-Cog in secondary care



## ADDITIONAL TABLES

Table 1. Overview of study characteristics

Study ID	Country	Study participants (N)	Mean age in years (SD)	Female gender %	Level of education	Mini-Cog scoring	Reference standard	Dementia prevalence N (%; 95% CI)	Dementia subtype N (%)
<a href="#">Clionsky 2010</a>	USA	1752 records available to review authors; 702	78.2 (7.2)	61.0	12.8 years (+/-3.1)	As per <a href="#">Borson 2000</a>	DSM-IV	516 (73.5; 70.1 to 76.6%)	Alzheimer's disease 402 (57.6%)

**Table 1. Overview of study characteristics** (Continued)

		(40.1%) records from Neuropsychology Group 2 used to describe test accuracy of Mini-Cog							3); frontotemporal dementia 71 (10.1); vascular dementia 24 (3.4); mixed or other dementia 19 (2.7)
<a href="#">Filho 2009</a>	Brazil	306; 211 (69.0%) included in analysis with 4 or fewer years of education	Dementia 74.0 (5.8) No dementia 72.0 (5.0)	72.5	Whole included sample $\leq 4$ years	Multiple thresholds reported including scoring as per <a href="#">Borson 2000</a>	DSM-IV	68 (32.2; 26.3 to 38.8%)	Binary classification dementia or no dementia, dementia subtype not reported
<a href="#">Milian 2012</a>	Germany	502; all included in analysis	Dementia 75.0 (8.5) No cognitive impairment 73.1 (5.5)	61.4	$\leq 8$ years: 47.7%; 9 to 11 years: 26.3%; $\geq 12$ years: 26.0%	As per <a href="#">Borson 2000</a>	DSM-IV, ICD-10, NINCDS-ADRDA	438 (87.3; 84.1 to 89.9%)	Alzheimer's disease 215 (49.1); vascular dementia 37 (8.4); vascular and Alzheimer's disease 107 (24.4); Parkinson's disease dementia 10 (2.3); frontotemporal lobar degeneration 6 (1.4); dementia with Lewy bodies



(Continued)

BIOSIS Citation Index 1926 to present (ISI Web of Science) [Date of most recent search 12 March 2019]	Topic=("mini-cog*" OR "minicog*" OR (MCE AND dement*) OR (MCE AND alzheimer*))	Sept 2012: 33 Jul 2013: 7 Feb 2015: 9 Mar 2019: 25
Web of Science Core Collection (1945 to present) (ISI Web of Science) [Date of most recent search 12 March 2019]	Topic=("mini-cog*" OR "minicog*" OR (MCE AND dement*) OR (MCE AND alzheimer*))	Sept 2012: 93 Jul 2013: 20 Feb 2015: 35 Mar 2019: 102
LILACS (BIREME) [Date of most recent search 12 March 2019]	"mini-cog" OR minicog OR (MCE AND dementia) OR (MCE AND demencia) OR (MCE AND demência) OR (MCE AND alzheimer\$)	Sept 2012: 2 Jul 2013: 2 Feb 2015: 2 Mar 2019: 13
Total before automated de-duplication		1658
Total after automated de-duplication and first assessment		468

**Search narrative:** the searches focus on a single concept - the index test. However, in order to ensure additional sensitivity, a broad search for neuropsychological and cognitive tests is run to populate the Cochrane Dementia and Cognitive Improvement Group's DTA register. This search is run every six months in MEDLINE and Embase (OvidSP). The most recent search was run in February 2019. The MEDLINE search can be seen below:

1. "word recall".ti,ab.
2. ("7-minute screen" or "seven-minute screen").ti,ab.
3. ("6 item cognitive impairment test" or "six-item cognitive impairment test").ti,ab.
4. "6 CIT".ti,ab.
5. "AB cognitive screen".ti,ab.
6. "abbreviated mental test".ti,ab.
7. "ADAS-cog".ti,ab.
8. AD8.ti,ab.
9. "inform\* interview".ti,ab.
10. "animal fluency test".ti,ab.
11. "brief alzheimer\* screen".ti,ab.
12. "brief cognitive scale".ti,ab.
13. "clinical dementia rating scale".ti,ab.
14. "clinical dementia test".ti,ab.
15. "community screening interview for dementia".ti,ab.
16. "cognitive abilities screening instrument".ti,ab.
17. "cognitive assessment screening test".ti,ab.
18. "cognitive capacity screening examination".ti,ab.
19. "clock drawing test".ti,ab.
20. "deterioration cognitive observee".ti,ab.
21. ("Dem Tect" or DemTect).ti,ab.
22. "object memory evaluation".ti,ab.
23. "IQCODE".ti,ab.
24. "mattis dementia rating scale".ti,ab.
25. "memory impairment screen".ti,ab.

(Continued)

26. "minnesota cognitive acuity screen".ti,ab.
27. "mini-cog".ti,ab.
28. "mini-mental state exam\*".ti,ab.
29. "mmse".ti,ab.
30. "modified mini-mental state exam".ti,ab.
31. "3MS".ti,ab.
32. "neurobehavioral cognitive status exam\*".ti,ab.
33. "cognistat".ti,ab.
34. "quick cognitive screening test".ti,ab.
35. "QCST".ti,ab.
36. "rapid dementia screening test".ti,ab.
37. "RDST".ti,ab.
38. "repeatable battery for the assessment of neuropsychological status".ti,ab.
39. "RBANS".ti,ab.
40. "rowland universal dementia assessment scale".ti,ab.
41. "rudas".ti,ab.
42. "self-administered gerocognitive exam\*".ti,ab.
43. ("self-administered" and "SAGE").ti,ab.
44. "self-administered computerized screening test for dementia".ti,ab.
45. "short and sweet screening instrument".ti,ab.
46. "sassi".ti,ab.
47. "short cognitive performance test".ti,ab.
48. "syndrome kurztest".ti,ab.
49. ("six item screener" or "6-item screener").ti,ab.
50. "short memory questionnaire".ti,ab.
51. ("short memory questionnaire" and "SMQ").ti,ab.
52. "short orientation memory concentration test".ti,ab.
53. "s-omc".ti,ab.
54. "short blessed test".ti,ab.
55. "short portable mental status questionnaire".ti,ab.
56. "spmsq".ti,ab.
57. "short test of mental status".ti,ab.
58. "telephone interview of cognitive status modified".ti,ab.
59. "tics-m".ti,ab.
60. "trail making test".ti,ab.
61. "verbal fluency categories".ti,ab.
62. "WORLD test".ti,ab.
63. "general practitioner assessment of cognition".ti,ab.
64. "GPCOG".ti,ab.
65. "Hopkins verbal learning test".ti,ab.
66. "HVRT".ti,ab.
67. "time and change test".ti,ab.
68. "modified world test".ti,ab.
69. "symptoms of dementia screener".ti,ab.
70. "dementia questionnaire".ti,ab.
71. "7MS".ti,ab.
72. ("concord informant dementia scale" or CIDS).ti,ab.
73. (SAPH or "dementia screening and perceived harm\*").ti,ab.
74. or/1-73

(Continued)

75. exp Dementia/
76. Delirium, Dementia, Amnesic, Cognitive Disorders/
77. dement\*.ti,ab.
78. alzheimer\*.ti,ab.
79. AD.ti,ab.
80. ("lewy bod\*" or DLB or LBD or FTD or FTLD or "frontotemporal lobar degeneration" or "frontaltemporal dement\*").ti,ab.
81. "cognit\* impair\*".ti,ab.
82. (cognit\* adj4 (disorder\* or declin\* or fail\* or function\* or degenerat\* or deteriorat\*)).ti,ab.
83. (memory adj3 (complain\* or declin\* or function\* or disorder\*)).ti,ab.
84. or/75-83
85. exp "sensitivity and specificity"/
86. "reproducibility of results"/
87. (predict\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
88. (identif\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
89. (discriminat\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
90. (distinguish\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
91. (differenti\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
92. diagnos\*.ti.
93. di.fs.
94. sensitivit\*.ab.
95. specificit\*.ab.
96. (ROC or "receiver operat\*").ab.
97. Area under curve/
98. ("Area under curve" or AUC).ab.
99. (detect\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
100. sROC.ab.
101. accura\*.ti,ab.
102. (likelihood adj3 (ratio\* or function\*)).ab.
103. (conver\* adj3 (dement\* or AD or alzheimer\*)).ti,ab.
104. ((true or false) adj3 (positive\* or negative\*)).ab.
105. ((positive\* or negative\* or false or true) adj3 rate\*).ti,ab.
106. or/85-105
107. exp dementia/di
108. Cognition Disorders/di [Diagnosis]
109. Memory Disorders/di
110. or/107-109
111. \*Neuropsychological Tests/
112. \*Questionnaires/
113. Geriatric Assessment/mt
114. \*Geriatric Assessment/
115. Neuropsychological Tests/mt, st
116. "neuropsychological test\*".ti,ab.
117. (neuropsychological adj (assess\* or evaluat\* or test\*)).ti,ab.
118. (neuropsychological adj (assess\* or evaluat\* or test\* or exam\* or battery)).ti,ab.
119. Self report/
120. self-assessment/ or diagnostic self evaluation/
121. Mass Screening/
122. early diagnosis/
123. or/111-122

(Continued)

124. 74 or 123  
 125. 110 and 124  
 126. 74 or 123  
 127. 84 and 106 and 126  
 128. 74 and 106  
 129. 125 or 127 or 128  
 130. exp Animals/ not Humans.sh.  
 131. 129 not 130

## Appendix 2. Assessment of methodological quality table QUADAS-2 tool

Domain	Patient selection	Index test	Reference standard	Flow and timing
Description	Describe methods of patient selection: describe included patients (prior testing, presentation, intended use of index test and setting)	Describe the index test and how it was conducted and interpreted	Describe the reference standard and how it was conducted and interpreted	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2 x 2 table (refer to flow diagram): describe the time interval and any interventions between index test(s) and reference standard
Signalling questions (yes, no, unclear)	Was a consecutive or random sample of patients enrolled? Was a case-control design avoided? Did the study avoid inappropriate exclusions?	Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it prespecified?	Is the reference standard likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index test?	Was there an appropriate interval between index test(s) and reference standard? Did all patients receive the same reference standard? Were all patients included in the analysis?
Risk of bias (high, low, unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct, or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability (high, low, unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or its interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	-

## **Appendix 3. Anchoring statements to assist with assessment of risk of bias**

### **Domain 1: patient selection**

#### **Risk of bias: could the selection of patients have introduced bias? (high, low, unclear)**

##### **Was a consecutive or random sample of patients enrolled?**

Where sampling is used, the methods least likely to cause bias are consecutive sampling or random sampling, which should be stated and/or described. Non-random sampling or sampling based on volunteers is more likely to be at high risk of bias.

##### **Was a case-control design avoided?**

Case-control study designs have a high risk of bias, but are sometimes the only studies available especially if the index test is expensive and/or invasive. Nested case-control designs (systematically selected from a defined population cohort) are less prone to bias, but they will still narrow the spectrum of patients that receive the index test. Study designs (both cohort and case-control) that may also increase bias are those designs where the study team deliberately increase or decrease the proportion of participants with the target condition, for example a population study may be enriched with extra dementia participants from a secondary care setting.

##### **Did the study avoid inappropriate exclusions?**

We will automatically grade the study as unclear if exclusions are not detailed (pending contact with study authors). Where exclusions are detailed, the study will be graded as 'low risk' if the review authors consider the exclusions to be appropriate. Certain exclusions common to many studies of dementia are: medical instability; terminal disease; alcohol/substance misuse; concomitant psychiatric diagnosis; other neurodegenerative condition. However, if 'difficult to diagnose' groups are excluded this may introduce bias, so exclusion criteria must be justified. For a community sample we would expect relatively few exclusions. We will label post hoc exclusions 'high risk' of bias.

##### **Applicability: are there concerns that the included patients do not match the review question? (high, low, unclear)**

The included patients should match the intended population as described in the review question. If not already specified in the review inclusion criteria, setting will be particularly important - the review authors should consider population in terms of symptoms; pre-testing; potential disease prevalence. We will classify studies that use very selected participants or subgroups as having low applicability, unless they are intended to represent a defined target population, for example people with memory problems referred to a specialist and investigated by lumbar puncture.

### **Domain 2: index test**

#### **Risk of bias: could the conduct or interpretation of the index test have introduced bias? (high, low, unclear)**

##### **Were the index test results interpreted without knowledge of the reference standard?**

Terms such as 'blinded' or 'independently and without knowledge of' are sufficient; full details of the blinding procedure are not required. This item may be scored as 'low risk' if explicitly described or if there is a clear temporal pattern to the order of testing that precludes the need for formal blinding, that is all (neuropsychological test) assessments were performed before the dementia assessment. As most neuropsychological tests are administered by a third party, knowledge of dementia diagnosis may influence their ratings; tests that are self-administered, for example using a computerised version, may have less risk of bias.

**Were the index test thresholds prespecified?**

For neuropsychological scales there is usually a threshold above which participants are classified as 'test positive'; this may be referred to as threshold, clinical cut-off, or dichotomisation point. Different thresholds are used in different populations. A study is classified as at higher risk of bias if the authors define the optimal cut-off post hoc based on their own study data. Certain papers may use an alternative methodology for analysis that does not use thresholds, and these papers should be classified as not applicable.

**Were sufficient data on (neuropsychological test) application given for the test to be repeated in an independent study?**

Particular points of interest include method of administration (e.g. self-completed questionnaire versus direct questioning interview); nature of informant; language of assessment. If a novel form of the index test is used, for example a translated questionnaire, details of the scale should be included and a reference given to an appropriate descriptive text, and there should be evidence of validation.

**Applicability: are there concerns that the index test, its conduct, or its interpretation differ from the review question? (high, low, unclear)**

Variations in the length, structure, language, and/or administration of the index test may all affect applicability if they vary from those specified in the review question.

**Domain 3: reference standard****Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias? (high, low, unclear)****Is the reference standard likely to correctly classify the target condition?**

Commonly used international criteria to assist with clinical diagnosis of dementia include those detailed in the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) and 10th Revision of the International Classification of Diseases (ICD-10). Criteria specific to dementia subtypes include but are not limited to National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria for Alzheimer's dementia; McKeith criteria for Lewy body dementia; Lund criteria for frontotemporal dementias; and the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria for vascular dementia. Where the criteria used for assessment are not familiar to the review authors and the Cochrane Dementia and Cognitive Improvement Group, this item should be classified as 'high risk of bias'.

**Were the reference standard results interpreted without knowledge of the results of the index test?**

Terms such as 'blinded' or 'independent' are sufficient; full details of the blinding procedure are not required. This may be scored as 'low risk' if explicitly described or if there is a clear temporal pattern to order of testing, that is all dementia assessments performed before (neuropsychological test) testing.

Informant rating scales and direct cognitive tests present certain problems. It is accepted that informant interview and cognitive testing is a usual component of clinical assessment for dementia, however specific use of the scale under review in the clinical dementia assessment should be scored as high risk of bias.

**Was sufficient information on the method of dementia assessment given for the assessment to be repeated in an independent study?**

Particular points of interest for dementia assessment include the training and expertise of the assessor; whether additional information was available to inform the diagnosis (e.g. neuroimaging, other neuropsychological test results); and whether this was available for all participants. High risk of bias if method of dementia assessment not described.

**Applicability: are there concerns that the target condition as defined by the reference standard does not match the review question? (high, low, unclear)**

It is possible that some methods of dementia assessment, although valid, may diagnose a far smaller or larger proportion of participants with disease than in usual clinical practice. For example, the current reference standard for vascular dementia may underdiagnose compared to usual clinical practice. In this instance the item should be rated as having poor applicability.

#### **Domain 4: patient flow and timing**

**Risk of bias: could the patient flow have introduced bias? (high, low, unclear)**

**Was there an appropriate interval between the index test and reference standard?**

For a cross-sectional study design, there is potential for the participant to change between assessments, however dementia is a slowly progressive disease that is not reversible. The ideal scenario would be a same-day assessment, but longer periods of time (e.g. several weeks or months) are unlikely to lead to a high risk of bias. For delayed-verification studies, the index and reference tests are necessarily separated in time given the nature of the condition.

**Did all participants receive the same reference standard?**

There may be scenarios where participants who score 'test positive' on the index test have a more detailed assessment for the target condition. Where dementia assessment (or reference standard) differs between participants, this should be classified as high risk of bias.

**Were all participants included in the final analysis?**

Attrition will vary with study design. Delayed-verification studies will have higher attrition than cross-sectional studies due to mortality, and it is likely to be greater in participants with the target condition. Dropouts (and missing data) should be accounted for. Attrition that is higher than expected (compared to other similar studies) should be treated as high risk of bias. We have defined a cut-off of greater than 20% attrition as being high risk, but this will be highly dependent on the length of follow-up in individual studies.

## **CONTRIBUTIONS OF AUTHORS**

CCHC assisted with protocol development, extraction of data, contributing to drafts of the manuscript.

BAF assisted with protocol development, extraction of data, contributing to drafts of the review.

JKB performed title selection, data extraction, 'Risk of bias' assessment, and completed the first draft of the manuscript.

NS assisted with protocol development, assisting with the database searches, and providing comments on drafts of the manuscript.

SSG assisted with protocol development and review of drafts of the manuscript.

NH assisted with protocol development and reviews of drafts of the manuscript.

VN assisted with protocol development, reviews of drafts of the manuscript, and methodological input into presentation of statistical results.

TJQ performed title selection, data extraction, 'Risk of bias' assessment, and provided supervision and comments on the final manuscript.

ANS assisted with creation of the search strategy, initial title searching, and provided comments on the final manuscript.

DPS assisted with protocol development, data extraction, 'Risk of bias' assessment, supervision, and comments on drafts of the manuscript and the final manuscript.

## DECLARATIONS OF INTEREST

Calvin CH Chan: none known

Bruce A Fage: none known

Jennifer K Burton: none known

Nadja Smailagic: none known

Sudeep S Gill: none known

Nathan Herrmann: received consultancy payment from Pfizer

Vasilis Nikolaou: none known

Terry J Quinn: none known

Anna H Noel-Storr: none known

Dallas P Seitz: participated as a site investigator on a trial sponsored by Hoffmann La Roche

## SOURCES OF SUPPORT

### Internal sources

- No sources of support supplied

### External sources

- Terry Quinn, UK.

TQ is supported by the joint Chief Scientist Office and Stroke Association Senior Clinical Lectureship

- Jennifer Kirsty Burton, UK.

JKB is supported by an NHS Education for Scotland, Scottish Clinical Research Excellence Development Scheme Clinical Lectureship

- NIHR, UK.

This review was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Dementia and Cognitive Improvement Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health.

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The protocol stated in 'Selection of studies' that studies had to: "Report estimates of test reproducibility, if completed within the study". In response to peer reviewers' comments, this text was moved to the data extraction section as it was not a mandatory item to determine study eligibility.

We updated statistical analysis text, as some studies did not provide numbers of true and false positives and negatives, but gave summary test accuracy data which was entered into Review Manager 5.

We did not conduct planned quantitative analyses, sensitivity analyses, and investigations of heterogeneity due to the methodological heterogeneity identified which made pooling of data inappropriate.